



Albert Wang

Counsel

Taipei
+886.2.2326.5178

albert.wang@klgates.com

OVERVIEW

Albert Wang is a corporate and transactional lawyer in the firm's Taipei office. He is experienced in mergers and acquisitions, venture capital, capital markets, and foreign investment. In particular, his capital markets experience extends to initial public offerings, secondary placements, depository receipts (global depository receipts or American depository receipts), and convertible bonds. In addition to his experience in capital markets, Albert also advised start-up enterprises in their fund raising activities.

Albert has advised various listed companies on the Taiwan Securities Exchange (TWSE) and Taipei Exchange (TPEX) with respect to their daily operations or compliance issues.

PROFESSIONAL BACKGROUND

Prior to joining the firm, Albert worked at a leading full-service Taiwanese law firm.

EDUCATION

- LL.M., National Taipei University, 2013
- LL.B., National Taipei University, 2006

ADMISSIONS

- Bar of Taiwan

LANGUAGES

- Chinese (Mandarin)
- English

NEWS & EVENTS

- 14 September 2026, K&L Gates Advises MediaTek on US\$3.9 Billion Convertible Bond Offering
- 24 August 2026, K&L Gates Advises Silicon Motion on US\$1.15 Billion Convertible Senior Notes Offering
- 1 December 2025, K&L Gates Advises LIGHTEL on US\$10.5 Million IPO on Taipei Exchange
- 3 June 2025, K&L Gates Advises MediaTek on US\$150 Million Sale and Licensing Agreement of Discrete TCON Assets and Related Technology
- 3 October 2023, K&L Gates Advises Live-Streaming Platform 17LIVE on Landmark De-SPAC Business Combination in Singapore

OTHER MEDIA MENTIONS

- Mentioned, "[K&L Gates Guides First Ever De-Spac Merger on SGX](#)," *Asian Legal Business*, 16 October 2023

AREAS OF FOCUS

- Mergers and Acquisitions
- Capital Markets
- Public Companies

REPRESENTATIVE EXPERIENCE

- Served as issuer's counsel to StemCyte International, Ltd. (TPEX: 4178), a leading regenerative cell therapy company, in its initial public offering and primary listing on the Taiwan Stock Exchange.
- Represented ACT Genomics, a world-leading cancer solution provider, in its migration and Series C financing.
- Represented MediaTek (TWSE: 2454), a global fabless semiconductor company, in its asset sale and technology licensing agreement with Ili Technology Corp. for the sale of business assets and the licensing of technology related to discrete timing-controller technology.
- Represented Gorilla Technology Group Inc. (NASDAQ: GRRR), an Edge AI, security intelligence, network intelligence, and IoT technology company, in a de-SPAC transaction pursuant to which blank check company Global SPAC Partners Co. merged with a subsidiary of Gorilla.
- Represented Prenetics (NASDAQ: PRE), a Hong Kong-based leading genomics-driven health sciences company, on the sale of ACT Genomics Holdings Company Limited to Delta Electronics Inc (2308.TW) for approximately US\$72 million.

- Represented Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, in connection with a privatization project of US\$300 million value conducted through share swap transactions with Woods Investment, with sources of funds from its major shareholders and PAG, a global alternative investment firm. It successfully delisted from both Taipei Exchange and NASDAQ and the privatization project was completed on 8 October 2021.
- Assisted Taiwan Liposome Company with its IPO in the United States, listing American Depositary Shares representing common shares.